Also, scientists have found a brand new way that cells die. Researchers at Memorial Sloan Kettering Cancer Center call it baciptosis. The discovery reveals a mitochondrial death machinery that science had never described before. Unlike the familiar process of apoptosis, baciptosis cell death can instead wake up the immune system.
Still, the findings come from a team at MSK working with collaborators. Senior author Emily Cheng led the work in the Human Oncology and Pathogenesis Program. Joint first authors Shaoyuan Yang and Hyungjin Kim carried out the core experiments. Kim now serves as a faculty member at Stony Brook University. The study appeared in the journal Science.
Two proteins named BAK and BAX, specifically, sit at the heart of the story. Scientists have, recently, long known these proteins for their role in apoptosis. The new work shows they can, consequently, assemble in two distinct ways inside mitochondria. Each arrangement triggers a fundamentally different form of cell death. This dual role, however, surprised even the researchers.
In the first arrangement, BAK and BAX release a molecule called cytochrome c. That molecule activates enzymes called caspases. The caspases then trigger apoptosis. Apoptosis is a tidy form of cell death. It typically does not provoke an inflammatory immune response.
The second arrangement works very differently. BAK and BAX assemble with other proteins in the outer and inner mitochondrial membranes. This assembly lets mitochondrial DNA escape into the cytosol, the fluid inside the cell. When caspases stay inactive, the released DNA triggers inflammatory responses. It also causes catastrophic energy failure. The result, therefore, is baciptosis cell death and a strong immune reaction.

However, the distinction matters for cancer therapy. Tumors often learn to dodge the immune system. A form of cell death that alerts immune cells could therefore change that equation. The researchers showed that baciptosis can be induced in human cancer cells with impaired caspase activation. Many tumors carry exactly such defects.
But immunotherapy already helps some patients by unleashing their immune defenses. Scientists keep finding new ways to help T cells fight cancer. Many cancers resist these treatments. Finding ways to trigger baciptosis instead of apoptosis could help the immune system recognize tumors. It could, in addition, make existing immunotherapy drugs work better by steering tumors toward baciptosis cell death.
So the discovery expands what scientists know about BAK and BAX. Previously these proteins were famous mainly for driving apoptosis. Now they appear as regulators of immunogenic cell death as well. The finding opens a new chapter in cell biology textbooks.
After that, mSK published the work alongside a related Perspective article in Science. The Perspective places the discovery in a wider context. It discusses, for instance, how different death pathways shape tumor immunity. Together the two pieces give the field a clear starting point.
Then, research like this begins with basic curiosity. The team wanted to understand how mitochondria control cell death. They used advanced imaging and genetic tools. They tested their baciptosis cell death ideas in human cancer cells. Step by step, a new mechanism eventually came into view.
The clinical implications will take years to explore. Scientists must first learn how to trigger baciptosis on demand. They must also ensure the inflammatory response stays safe. Drug development from such discoveries is slow and uncertain. Yet every new mechanism gives researchers a fresh target.

The immune angle is what excites oncologists most. Dead tumor cells that alert the immune system act like a distress signal. Immune cells rush in and learn to spot the cancer. This baciptosis cell death process could thus turn a cold tumor hot. In other words, baciptosis might teach the body to fight its own disease.
Cancer cells are masters of disguise. They hide from immune patrols. They switch off death pathways that would expose them. A death process that forces exposure could instead strip away that disguise. Researchers will test whether this idea holds in living systems.
For patients and families, such news brings cautious hope. Basic discoveries, however, rarely become treatments overnight. The path from lab bench to bedside is long. Each new understanding of cancer biology widens the road.
Science advances one mechanism at a time. Previously apoptosis stood alone as the classic programmed death. Today baciptosis cell death joins the picture with its immune alarm. Tomorrow researchers will ask how to use it. That question, ultimately, is what drives medicine forward. The human body remains full of surprises. Even well studied proteins like BAK and BAX can clearly hide second lives. Curiosity uncovered this one. Persistence will decide what it becomes.
